Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 2, Single-Arm Open-Label Study of DCC-2618 to Assess Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors Who Have Progressed On Prior Anticancer Therapies

Next Previous
X
Search
Trial Profile

A Multicenter Phase 2, Single-Arm Open-Label Study of DCC-2618 to Assess Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors Who Have Progressed On Prior Anticancer Therapies

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ripretinib (Primary) ; Sunitinib
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Acronyms INTRIGUE
  • Sponsors ZAI Lab

    • Most Recent Events

    • 08 Jan 2024 According to a Deciphera Pharmaceuticals media release, results of a ctDNA analysis from this trial will be published in the Nature Medicine in January 2024.
    • 14 Nov 2023 Primary endpoint (PFS assessed by independent central review) has been met, as per results published in the European Journal of Cancer.
    • 14 Nov 2023 Results assessing the efficacy and safety (data cut-off 20 July 2022) of ripretinib versus sunitinib as second-line treatment in Chinese gastrointestinal stromal tumor patients, published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top